- The pharmacological profile of apixaban2013 | First Faculty of Medicine, Third Faculty of Medicine
- Apixaban2014 | First Faculty of Medicine
- Apixabans2011 | First Faculty of Medicine, Third Faculty of Medicine
- Apixaban in patients with atrial fibrillation and impaired renal function - subanalysis of ARISTOTLE study2013 | Publication without faculty affiliation
- Apixaban, a new oral antithrombotic agent - Review of marketing authorisation studies2012 | Second Faculty of Medicine
- AMPLIFY-EXT study. Apixaban in the treatment of venous thromboembolism2013 | First Faculty of Medicine
- Apixaban (Eliquis) for prevention of thromboembolic events in patients with atril fibrillation2012 | First Faculty of Medicine
- Apixaban is more effective than warfarin in reduction of the incidence of strokes and bleeding in patients with atrial fibrillation irrespective of their risk profiles: subanalysis of ARISTOTLE trial2013 | Publication without faculty affiliation
- Apixaban has been available for the treatment of venous thromboembolic disease for more than two years +12017 | First Faculty of Medicine, Third Faculty of Medicine
- Apixaban (Eliquis(R)) was registered also for stroke and systemic embolic events prevention in atrial fibrillation patients by the end of 20122013 | First Faculty of Medicine
- Apixaban effective and safe in the treatment of acute venous thrombosis - another drug that changes practice2013 | First Faculty of Medicine
- Guidelines of Czech Association for Thrombosis and Haemostasis of the Czech Medical Association of J. E. Purkyně for safety treatment with new oral anticoagulants (NOAC) - dabigatran etexilate, apixaban and rivaroxaban2015 | First Faculty of Medicine
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | First Faculty of Medicine
- New indication of apixaban - prevention of strokes and peripheral embolizations in patients with atrial fibrillation2013 | First Faculty of Medicine
- Commentary on Aristotle study (Apixaban compared with warfarin in patients with atrial fibrillation)2011 | First Faculty of Medicine
- Andexanet alfa - specific antidote to severe bleeding after a treatment with apixaban or rivaroxaban2020 | Publication without faculty affiliation
- Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study2008 | Faculty of Medicine in Hradec Králové
- Comparison of new oral anticoagulants from the perspective of pharmacological features and clinical trials2013 | First Faculty of Medicine, Third Faculty of Medicine
- ARISTOTLE study - another milestone in anticoagulation therapy for atrial fibrillation2012 | Publication without faculty affiliation
- Apixaban ve srovnání s warfarinem v prevenci trombózy u trombotického antifosfolipidového syndromu2021 | First Faculty of Medicine
- Anticoagulation with new antithrombotic agents - recommendations for daily practice2013 | Publication without faculty affiliation
- Is concomitant aspirin helping novel oral anticoagulants? Focus on apixaban2014 | Second Faculty of Medicine
- Laboratory monitoring of new direct anticoagulants2014 | First Faculty of Medicine
- Direct costs in patients with nonvalvular atrial fibrillation newly indicated to apixaban: a retrospective-prospective single-arm cohort study2022 | First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University
- Comment on a study2013 | First Faculty of Medicine
- What we expect from anticoagulant therapy in 20142014 | Publication without faculty affiliation
- New direct oral anticoagulants (NOAC) - solutions to potential problems with coagulation assessment2014 | First Faculty of Medicine
- Monitoring of the efficacy of novel oral anticoagulants2014 | Second Faculty of Medicine
- Novel oral anticoagulants - the advantages and drawbacks of the therapy2015 | Third Faculty of Medicine